Clinical Trials Logo

Hepatic Impairment clinical trials

View clinical trials related to Hepatic Impairment.

Filter by:

NCT ID: NCT03626415 Completed - Hepatic Impairment Clinical Trials

A Hepatic Impairment Study for PF-04965842.

Start date: October 1, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.

NCT ID: NCT03555539 Completed - Hepatic Impairment Clinical Trials

Study of Danicopan in Participants With Hepatic Impairment

Start date: May 1, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACH-0144471 (danicopan) in participants with hepatic impairment (HI) as compared to healthy matched participants.

NCT ID: NCT03546608 Completed - Hepatic Impairment Clinical Trials

Tepotinib Hepatic Impairment Trial

Start date: June 13, 2018
Phase: Phase 1
Study type: Interventional

The study will investigate the effect of various degrees of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of tepotinib.

NCT ID: NCT03534843 Completed - Clinical trials for Hepatocellular Carcinoma

A Comparison Between Child-Pugh and Albumin-Bilirubin Scores

Start date: January 1, 2005
Phase:
Study type: Observational

To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma

NCT ID: NCT03440424 Completed - Hepatic Impairment Clinical Trials

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Start date: January 26, 2018
Phase: Phase 1
Study type: Interventional

This study will be conducted to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of lemborexant after a single-dose administration.

NCT ID: NCT03423446 Completed - Hepatic Impairment Clinical Trials

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Start date: November 28, 2017
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the effect of severe hepatic impairment on the pharmacokinetics (PK) of telotristat ethyl (TE) ( LP-778902 active moiety, metabolite), following administration of a single dose of TE 250 mg (1 x 250-mg tablet) compared to healthy, demographically-matched subjects with normal hepatic function.

NCT ID: NCT03397888 Completed - Hepatic Impairment Clinical Trials

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Start date: November 16, 2017
Phase: Phase 1
Study type: Interventional

Single center, prospective open label PK and PD study of betrixaban in subjects with mild and moderate hepatic impairment vs healthy volunteers.

NCT ID: NCT03376841 Completed - Hepatic Impairment Clinical Trials

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Start date: June 6, 2017
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability profiles of cenicriviroc (CVC) and its metabolites (M-I and M-II) in participants with severely impaired hepatic function compared with matched healthy participants following single-dose administration

NCT ID: NCT03369002 Completed - Hepatic Impairment Clinical Trials

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Start date: November 27, 2017
Phase: Phase 1
Study type: Interventional

This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of seladelpar following administration of a single oral dose in subjects with varying degrees of hepatic impairment (HI) compared to healthy matched control subjects with normal hepatic function.

NCT ID: NCT03359850 Completed - Neoplasms Clinical Trials

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

Start date: February 20, 2018
Phase: Phase 1
Study type: Interventional

Niraparib (Zejula®)is extensively metabolized and eliminated primarily by hepatic and renal pathways. The purpose of this study is to evaluate pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment, for the purpose of providing recommendations to guide the initial dose and dose titration in this patient population.